Erenumab Dose 1
Phase 3
AmgenErenumab Dose 1 is one of 37 therapeutic programs targeting Migraine. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
105 competitors in Migraine
#DrugCompanyPhaseTrials
1Avicel
SSanthera Pharmaceuticals
Phase 3
Aspirin /d
TThe First Affiliated Hospital with Nanjing Medical University
Phase 3
Flunarizine
AAspartes Pharmaceuticals, Inc.
Phase 3
BAT7104
TevaPhase 3
Erenumab Dose 1
AmgenPhase 3
Tizanidine Hydrochloride
EElan Pharmaceuticals
Phase 3
Bayer Aspirin
BayerPreclinical
Cymbalta
Jazz PharmaceuticalsPreclinical
Adempas
BayerPreclinical
Cervidil
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Migraine1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Erenumab Dose 1. EMBL-EBI & Wellcome Sanger Institute.
- [3]